Last reviewed 2026-04-20 · How we verify

Ferric carboxymaltose IV

Ferric carboxymaltose IV, marketed by Columbia University, is an intravenous iron replacement therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports its competitive position. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Effect of Intravenous Iron on Quality of Life in Older Patients With Acute Coronary Syndrome (PHASE4)
• The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department (PHASE4)
• EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY (PHASE1)
• The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension (PHASE4)
• An Open Study on the Efficacy of Iron Therapy Using iv Iron Relative to Oral Iron for Increasing LV Systolic Function (NA)
• IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study (PHASE2, PHASE3)
• Comparison of the Mean Change in Hemoglobin With Ferric Carboxymaltose and IV Iron Sucrose in Anemic Antenatal Patients (NA)
• Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Ferric carboxymaltose IV CI brief — competitive landscape report
• Ferric carboxymaltose IV updates RSS · CI watch RSS
• Columbia University portfolio CI